erlotinib — drug repurposing hypotheses

CROSS-DOMAIN PATTERN

Same drug, multiple disease domains

erlotinib appears in hypotheses across 6 disease domains: Alzheimer, Depression, Epilepsy, Glioblastoma, Pancreatic cancer, Rheumatoid arthritis. Shared mediators that recur across at least two of those domains: EGFR.

Aggregated from the catalog. Biological interpretation of any multi-indication mechanism would require independent validation — this is a structural observation only.

ALL HYPOTHESES

Repurposing candidates for erlotinib

Alzheimer 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	Alzheimer's disease	0.396	High	partial evidence	none

Depression 1

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	MDD	0.208	Mid	novel signal	none

Epilepsy 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	lesional focal epilepsy	0.208	Mid	novel signal	none
EGFR	juvenile focal epilepsies	0.208	Mid	novel signal	none

Glioblastoma 3

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	glioblastoma	0.457	High	reproduces known	completed
EGFR	worse survival	0.396	High	reproduces known	none
EGFR	glioblastoma aggressiveness	0.396	High	novel signal	none

Pancreatic cancer 5

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	pancreatic ductal adenocarcinoma	0.373	High	reproduces known	active
EGFR	pancreatic adenocarcinoma	0.330	High	reproduces known	active
EGFR	pancreatic intraepithelial neoplasia	0.269	Mid	partial evidence	none
EGFR	survival	0.269	Mid	reproduces known	completed
EGFR	AGR2-dependent oncogenic phenotypes	0.269	Mid	novel signal	none

Rheumatoid arthritis 2

Mediator	Outcome	Score	Tier	Lit. status	Trial
EGFR	rheumatoid arthritis	0.269	Mid	partial evidence	none
EGFR	cardiovascular disease	0.208	Mid	partial evidence	active

← All drugs